Analyst Price Target is $4.70
▲ +547.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Outset Medical in the last 3 months. The average price target is $4.70, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 547.65% upside from the last price of $0.73.
Current Consensus is
Moderate Buy
The current consensus among 5 polled investment analysts is to moderate buy stock in Outset Medical. This rating has held steady since September 2024, when it changed from a Hold consensus rating.
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Read More